Group items tagged

attention deficit disorder symptoms children ADHD IN KIDS

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has raised concerns within the healthcare community. This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024. Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in managing conditions like attention deficit hyperactivity disorder (ADHD). However, the scarcity of these specific strengths poses challenges for patients reliant on this medication. Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including the UK, the US and Australia. Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand, potentially resulting in treatment interruptions for patients.

In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement with India. According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue. It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of doctors. Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.

Tynor Functional Knee Support is specially designed to support knees which are injured or not working properly due to old age. It stabilizes knees during rotational and anteroposterior forces and cures the ligamentous knee injuries. It provides support to the knees by wrapping around them and thus facilitates their compression. It provides flexibility and easy movement of the knee. It is made of soft, durable fabric which can be stretched in four ways. It mimics the natural knee joint. It can bear the load and shock exerted on it from the external forces leaving the knee totally free from pressure. It contains no buckling or vaso constriction which might hinder comfort. It ensures the proper circulation of blood. It compresses the patellar region and hold it in right position and thus can be used for patellofemoral diseases. It is easy to maintain. Tynor Functional Knee Support Functional knee Support is an anterior opening device, which offers the advantage of controlled compression around the knee and a rigid lateral support and immobilization. It allows normal flexion and free movement of the knee joint. Anterio Open able Easy application Controlled compression. Perfect lateral splinting. Anatomical design. Tynor Functional Knee Support Features Bi axial heavy duty aluminum hinge Mimics the natural knee joint Ensures full weight bearing. Allows free flexion movement Four way stretchable fabric Controlled and comfortable compression No buckling No vaso constriction Enhanced comfort Open patella design Release patellar pressure Hold the patella in position Can be used for Patellofemoral diseases Wrap design with anterior closing Easy application and removal on swollen or asymmetric knees Easy application and removal for weak or geriatric patients. Allows customized compression Offers flexibility in sizing Ergonomic design Anti tourniquet effect - ensures no constriction to blood flow Better grip of the product to the bo

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.

A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages. NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and Hormone Replacement Therapy (HRT) drugs. The report highlights the impact of affected medicine supply issues on community pharmacies and patients. Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be as bad as they have ever been". She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.

Colonis, a subsidiary company of the Clinigen Group has received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD). Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25%-50%. Sleep onset insomnia in children with ADHD can affect their mood, attention, behaviour and school performance. Henno Welgemoed, Director of Medical Affairs at Colonis said: "We welcome the MHRA's approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks."

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition. The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services. The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand. Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

Healthcare professionals in the UK are being advised to avoid prescribing the migraine and antiseizure medication topiramate, commonly known by the brand name Topamax, to women and girls unless they fulfil the requirements of a Pregnancy Prevention Programme. This guidance follows new safety measures introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) following a major safety review, which highlighted a potential increased risk of neurodevelopmental disabilities in children exposed to topiramate during pregnancy. The Commission on Human Medicines (CHM) evaluated studies that examined the risks associated with using topiramate during pregnancy. These studies indicated that children born to mothers who took topiramate during pregnancy had an approximately 2 to 3 times higher risk of intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder. Based on CHM's recommendations, the MHRA now advises that topiramate should not be prescribed for treating epilepsy during pregnancy unless there is no suitable alternative.

Brain Tumors: To remove malignant or benign brain tumors causing symptoms or threatening health. Aneurysms: To repair or prevent rupture of brain aneurysms. Spinal Disorders: For conditions like herniated discs, spinal stenosis, or spinal tumors causing severe pain or neurological deficits. Traumatic Injuries: To address head or spinal cord injuries resulting from accidents or falls. Epilepsy: When seizures are not controlled by medication, surgery may be performed to remove the affected brain area. Parkinson's Disease: For deep brain stimulation to manage symptoms not controlled by medication. Chiari Malformations: To correct structural defects in the cerebellum. Peripheral Nerve Disorders: Such as carpal tunnel syndrome or nerve tumors. Spine and Neurosurgeon India ☎️Call us:- +91-9325887033

Having a child with Attention Deficit Hyperactivity Disorder (ADHD) can be a challenging, and at times a heartbreaking, experience, and is one that impacts many families. According to the Centers for Disease Control and Prevention, 4.7 million children in America have been diagnosed with ADHD.

Read this article on ways to build muscle, lose weight by eating certain foods

As for burning calories. It is logical to assume that it does not really matter how you create the deficit - through diet or physical activity. The latter will really help to lose weight if you need to lose about 1-2 kg. But when you want to lose more, you can't do without a diet. I ate right but now I have added physical activity in the form of calorie burning programs from https://bestbodyworkout.com/skinny-legs-big-upper-body/

Most Important Articles That You Must Read. Hope You Will Love These Articles :: https://cutt.ly/3VQhbIi https://cutt.ly/JVQhvvQ https://cutt.ly/pVQhmJE https://cutt.ly/hVzeMo4 https://cutt.ly/iVzryST https://cutt.ly/qVzrpUn https://cutt.ly/NVzrswB https://cutt.ly/0Vzrdzt https://cutt.ly/AVzrf7O https://cutt.ly/MVzrhNl https://cutt.ly/1Vzrlnr https://cutt.ly/bVzrcqf https://cutt.ly/TVzrDmb https://cutt.ly/uVzrHcC https://cutt.ly/jVzrKXI https://cutt.ly/UVzrXRe https://cutt.ly/CVzrC1e https://cutt.ly/CVzrBzX https://cutt.ly/iVzrNQk https://cutt.ly/rVzrMHH https://cutt.ly/6Vzr18a https://cutt.ly/8Vzr2w9 https://cutt.ly/CVztt6U https://cutt.ly/CVztukJ https://cutt.ly/OVztoO9 https://cutt.ly/KVztp35 https://cutt.ly/yVztslS https://cutt.ly/4Vztd0s https://cutt.ly/jVztgWa https://cutt.ly/3VzthGR https://cutt.ly/8Vztj6r https://cutt.ly/uVztldr https://cutt.ly/2VztYFl https://cutt.ly/aVztItp https://cutt.ly/PVztINm https://cutt.ly/bVztPUR https://cutt.ly/4VztSw0 https://cutt.ly/MVztDMn https://cutt.ly/nVc9VKj https://cutt.ly/rVc9BEv https://cutt.ly/SVc9Nvs

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by differences in brain function and activity impacting attention, executive functioning, and impulse control. It often manifests in childhood and can persist into adulthood. While commonly associated with hyperactivity and fidgeting, ADHD presents on a spectrum with diverse symptoms and varying intensities.The exact cause of What Is ADHD is not fully understood, but it's likely due to a complex interplay of genetic and environmental factors. Genetics play a significant role, with ADHD often running in families. However, environmental factors like prenatal exposure to certain substances, childhood trauma, and brain injuries can also contribute. Core Symptoms: The core symptoms of ADHD fall into three main categories: Inattention: Difficulty focusing, sustaining attention, making careless mistakes, easily distracted, forgetting tasks. Hyperactivity: Fidgeting, squirming, excessive movement, difficulty remaining seated, feeling restless. Impulsivity: Acting without thinking, blurting out answers, interrupting others, difficulty waiting turns. It's important to remember that not everyone with ADHD experiences all symptoms to the same degree. Some individuals might primarily struggle with inattention, while others exhibit more hyperactive or impulsive tendencies. Additionally, the presentation can change over time and across different situations.

Adderall is a trading name for the combination drug that includes 4 types of amphetamine salts (Amphetamine aspartate, dextroamphetamine sulfate, dextroamphetamine saccharate, and amphetamine sulfate). In this, the two main ingredients Amphetamine and dextroamphetamine are the central nervous system stimulants that help to pay attention, stay focused, and control uncontrollable behavioral activities. Both Adderall vs Methylphenidate (commonly known as Ritalin) are stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD). While they share the same goal of improving focus, attention, and reducing impulsivity, key differences exist in their composition, action, and side effects. Choosing the right one requires understanding these nuances and consulting a healthcare professional. Chemical Composition: Adderall: A brand name for a mixture of amphetamines (amphetamine and dextroamphetamine). These directly stimulate the central nervous system, increasing dopamine and norepinephrine levels. Methylphenidate: Not an amphetamine, but a psychostimulant that works by blocking the reuptake of dopamine and norepinephrine, essentially making them more available in the brain. Side Effects: Adderall: More likely to cause side effects like anxiety, insomnia, decreased appetite, headaches, and heart palpitations. Methylphenidate: More prone to causing side effects like nervousness, stomach upset, tics, and mood swings.